From the most anticipated trial updates to the latest in biomarkers and precision oncology, we’re incredibly grateful to all of the experts who contributed to VJOncology’s growing repository of short-format medical education. In case you weren’t able to attend the conference or simply wanted to review something you missed, our ESMO 2024 coverage is available here: https://www.vjoncology.com/event/esmo-2024/ .
Saying goodbye to sunny Barcelona wasn’t easy for VJOncology as ESMO wrapped up for another year. Our VJOncology team once again had the pleasure to catch up with some of the biggest brains in oncology, interviewing over 100 key opinion leaders across the congress period.
And for those of you who aren’t signed up to our newsletter yet, here are some of our Editor’s top picks:
🌟 Sanjay Popat, MBBS, FRCP, PhD
MARIPOSA-2: second interim OS of amivantamab and chemotherapy in non-small cell lung cancer
VJOncology Expert Editorial Board Member, Sanjay Popat, from The Royal Marsden NHS Foundation Trust, London, UK, joined us to talk about the second interim overall survival findings from the Phase III MARIPOSA-2 trial (NCT04487080)
🌟 Peter Schmid, FRCP, MD, PhD
KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in triple-negative breast cancer
We also spoke with another member of our Expert Editorial Board, Peter Schmid, FRCP, MD, PhD, Barts Cancer Institute, London, UK who discussed the final overall survival (OS) results from the Phase III KEYNOTE-522 trial (NCT03036488)
🌟 Domenica Lorusso, MD, PhD
KEYNOTE-A18: pembrolizumab + chemoradiotherapy improves OS in high-risk cervical cancer
In this interview, Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, discussed the second interim analysis of the Phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945), the findings of which supported the adoption of pembrolizumab and chemoradiotherapy as a new standard of care for the treatment of high-risk locally advanced cervical cancer.
We’ll be covering findings from the above trials and more in our “Highlights from ESMO 2024” episode of the VJOncology Podcast, which is now available on our website and on Apple Podcasts, Podbean, and Spotify! 🎧 🔦
Whilst the science kept our minds active, the OncoAlert 5k kept us physically active, as some of the VJOncology team headed out early Saturday morning to join our friends and colleagues from OncoAlert for a 5km run along the beach (worth it in the end for a view of the sunrise!). Thank you to Gil Morgan for organizing! 🏃♀️🌴
It was great to meet each of you at the VJOncology booth this year – we promise to bring more chocolates next year 🍫
And for those of you who missed us, don’t worry! You can still sign up for regular updates on our conference coverage and our other educational activities here ✉️💡
All in all, a big thank you to ESMO - European Society for Medical Oncology for organizing such a great conference. We can’t wait for ESMO 2025 – hope to see you then!
About VJOncology
The Video Journal of Oncology (VJOncology) is a leader in oncology news and education, providing healthcare professionals from around the globe with easy access to the latest updates in solid tumor research and expert opinion. Our Editorial Board and Team work closely to capture the most important and relevant information from major congresses and meetings, presenting this in engaging and easily-digestible digital formats for community oncologists to explore.
The continued success of VJOncology is in no small part down to independent support from industry. If you’re interested in supporting one of our Disease Channels or one of our other medical education programs, please get in contact with us here.
